Novartis AG is a Switzerland-based pharmaceutical company operating in the Healthcare sector, with a focus on innovative medicines and biotechnology. Headquartered in Basel, Switzerland, the company serves global markets through research, manufacturing, and commercial operations across multiple regions.

Novartis concentrates primarily on prescription medicines and advanced therapies, including biologics, gene therapies, and targeted treatments for complex diseases. Its portfolio spans key therapeutic areas such as oncology, cardiovascular diseases, immunology, neuroscience, and rare diseases.

The company maintains a global footprint across the Americas, Europe, Asia-Pacific, Africa, and the Middle East. Distribution channels include hospitals, clinics, retail pharmacy networks, and public health systems.

Novartis operates through integrated research and development centers, biotechnology facilities, and pharmaceutical manufacturing units. Market dynamics affecting its performance include patent cycles, regulatory frameworks, R&D investment requirements, pricing pressures, and global healthcare demand.

The company employs tens of thousands of people worldwide and supports its innovation pipeline through sustained investment in research and strategic partnerships.

Novartis shares trade in Switzerland on the SIX Swiss Exchange and in the United States through American Depositary Receipts (ADRs) under the ticker NVS.

History and Development

Novartis was formed in the mid-1990s through the merger of Ciba-Geigy and Sandoz, combining chemical, pharmaceutical, and biotechnology expertise into a single global entity.

Following its creation, the company focused on integrating operations, harmonizing research pipelines, and expanding its global presence. Over time, it strengthened its position in innovative medicines while also developing its generics and biosimilars operations through its Sandoz division.

Throughout the 2000s and 2010s, Novartis expanded its therapeutic portfolio and increased investments in biotechnology and advanced research platforms.

In recent years, the company has emphasized high-value innovative medicines, strategic portfolio optimization, and expansion of advanced therapies, while adapting to evolving regulatory environments and healthcare demands.

Today, Novartis positions itself as a global pharmaceutical company centered on innovation, specialized treatments, and long-term research-driven growth.

Additional Information

Novartis AG (United States) is listed on the NYSE and has a market capitalization of $302.88 billion, with shareholders equity totaling $41.95 billion.

The company employs approximately 105.794 people and operates in the Health sector, within the Main Medications industry.

Over the past 12 months, Novartis AG reported $56.69 billion in revenue, generating net income of $12.76 billion.

Key financial metrics include a P/E ratio of 23.74, a price-to-book (P/B) ratio of 7.22, and a trailing twelve-month dividend yield of 1.95%.

The company trades under the ticker NVS.